These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 20885448

  • 1. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma.
    Marchi LH, Paschoalin T, Travassos LR, Rodrigues EG.
    Cancer Gene Ther; 2011 Feb; 18(2):110-22. PubMed ID: 20885448
    [Abstract] [Full Text] [Related]

  • 2. Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo.
    Rodrigues EG, Garofalo AS, Travassos LR.
    Cytokines Cell Mol Ther; 2002 Feb; 7(3):107-16. PubMed ID: 12850810
    [Abstract] [Full Text] [Related]

  • 3. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.
    Pajtasz-Piasecka E, Rossowska J, Szyda A, Krawczenko A, Dus D.
    Oncol Rep; 2007 May; 17(5):1249-57. PubMed ID: 17390073
    [Abstract] [Full Text] [Related]

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C.
    Cancer Res; 2006 Jun 15; 66(12):6395-404. PubMed ID: 16778218
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice.
    Zhao F, Dou J, Wang J, Chu L, Tang Q, Wang Y, Li Y, Cao M, Hu W, Hu K, Feng He X, Gu N.
    Immunobiology; 2010 Jun 15; 215(2):89-100. PubMed ID: 19457579
    [Abstract] [Full Text] [Related]

  • 16. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ.
    Cancer Res; 2003 Oct 01; 63(19):6378-86. PubMed ID: 14559827
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF.
    Cancer Res; 2004 Aug 15; 64(16):5830-8. PubMed ID: 15313927
    [Abstract] [Full Text] [Related]

  • 19. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
    Kircheis R, Küpcü Z, Wallner G, Wagner E.
    Cytokines Cell Mol Ther; 1998 Jun 15; 4(2):95-103. PubMed ID: 9681248
    [Abstract] [Full Text] [Related]

  • 20. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.
    Cancer Gene Ther; 2000 Dec 15; 7(12):1543-56. PubMed ID: 11228533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.